GENE ONLINE|News &
Opinion
Blog

2022-05-13| Trials & Approvals

The FDA Granted These Three Companies Orphan Drug Designations in One Day

by Reed Slater
Share To
May 12 was a big day for advancing rare disease treatment as the FDA granted Orphan Drug Designation to Stealth BioTherapeutics, Neurocrine Biosciences, and Editas Medicine. Stealth BioTherapeutics aims to treat Duchenne muscular dystrophy, Neurocrine Biosciences is focused on chorea associated with Huntington’s disease, and Editas Medicine on beta thalassemia, a rare blood disorder.

It's free! Log in now to read

LOG IN SUBSCRIBE NOW
LATEST
West Nile and Usutu Viruses Detected in Wild Carnivore Populations in the Netherlands
2026-07-11
Norwegian Stakeholders Identify Implementation Challenges in Elder Abuse Prevention Guidelines for 2026 BMC Geriatrics Study
2026-07-11
Norwegian Stakeholders Identify Implementation Challenges in Elder Abuse Prevention Guidelines for 2026 BMC Geriatrics Study
2026-07-11
Biotech Stock Performance Gap Widens During Second Quarter of 2026
2026-07-11
PYGO2 Overexpression Linked to Increased Plasma Cell Proliferation in Multiple Myeloma Patients with 1q21 Amplification
2026-07-10
Sean Kaufman Faces Senate Scrutiny Over Past Vaccine Safety Comments Ahead of Confirmation Hearing
2026-07-10
Penn State College of Medicine Receives $2.5 Million Grant for Street Medicine Program
2026-07-10
READ MORE
EVENT
2026-07-08
ISSCR (Regenerative Medicine &Cell Therapy)
Montreal, Canada
2026-07-15
BIO Asia-Taiwan 2026 (APAC Biotech & Investment)
Taipei, Taiwan
2026-08-07
Healthy Ageing Tech Show (7-9 Aug, TAIPEI WTC) (Longevity, elder care & ageing tech)
Taipei, Taiwan
2026-09-02
BIO Asia Pacific (APAC Biotech & Smart Health)
Bangkok, Thailand
2026-09-16
BIOHK (16–19, Hong Kong) (Hong Kong biotech & investment)
Hong Kong
2026-10-07
BioJapan / HealthTECH JAPAN (Biotech, Medtech, Regenerative)
Yokohama, Japan
SEE MORE
Scroll to Top